Nancy Pelosi Discloses Up to $6 Million in Bullish Intel and Uber Call Options
Her first major trades since early 2026.
Already have an account? Sign in.
Her first major trades since early 2026.
Congress approves sweeping housing legislation to accelerate construction and limit Wall Street investors. Trump delays signing, but markets cheer the supply-boosting reforms.
Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.
The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.